Three Psychedelic Drug Applications Reach the FDA as Washington Debates Policy, Access and Review
Summary
Three psychedelic new drug applications are with the FDA as questions about psilocybin submissions, policy and access draw attention in Washington, D.C. Josh Hardman's notes from BrainFutures' Frontiers of Mental Health and Recovery cover ICER's review of Compass' psilocybin and the precedent of its Spravato assessment, as well as CDER Director Mike Davis's views on the FDA's role and its limits. They also address shifting Washington politics, an HHS ibogaine announcement, an NIMH funding opportunity and Delix's J&J-backed fundraising. The supplied material lists these subjects but does not provide the underlying discussion or conclusions.